Mark Sausen

Biography
Dr. Sausen has driven the planning, development and execution of projects in genetics and genomics for life sciences companies and academic research centers over the past fifteen years. Previously, as Vice President, Research and Development at PGDx, he led the development of our NGS-based in vitro diagnostic platforms, achieving proof of concept for plasma-based detection capabilities which contributed to an FDA breakthrough device designation. Dr. Sausen was most recently Scientific Director, Clinical Genetics and Genomics, at Bristol Myers Squibb. In this role, he co-led platform development and partnered strategies for liquid biopsy clinical development opportunities and guided exploratory genomics applications with respect to solid tumor disease biology, pharmacodynamics, and patient segmentation. He has also contributed to research at the Ludwig Center for Cancer Genetics and Therapeutics, the Helen F. Graham Cancer Center, and the Human Performance Laboratory. Dr. Sausen holds a Ph.D. in Cellular and Molecular Medicine from Johns Hopkins School of Medicine and has received numerous awards and research grants for his work in genomics and diagnostics.

Clinical Dx Showcase:
Personal Genome Diagnostics
PGDx empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide.

Enabling NGS-based Precision Oncology Testing Locally
The PGDx elio™ Platform has enabled the development of standardized tissue and liquid biopsy kits that ensure consistent results and quality of testing for laboratories worldwide. We empower clinicians to deliver potentially life-saving, biomarker-informed treatment plans by enabling in-house tumor profiling with our portfolio of IVD and RUO kitted solutions and streamlined bioinformatics.